Systematic illumination of druggable genes in cancer genomes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
By combining 6 druggable genome resources, we identify 6,083 genes as potential druggable genes (PDGs). We characterize their expression, recurrent genomic alterations, cancer dependencies, and therapeutic potentials by integrating genome, functionome, and druggome profiles across cancers. 81.5% of PDGs are reliably expressed in major adult cancers, 46.9% show selective expression patterns, and 39.1% exhibit at least one recurrent genomic alteration. We annotate a total of 784 PDGs as dependent genes for cancer cell growth. We further quantify 16 cancer-related features and estimate a PDG cancer drug target score (PCDT score). PDGs with higher PCDT scores are significantly enriched for genes encoding kinases and histone modification enzymes. Importantly, we find that a considerable portion of high PCDT score PDGs are understudied genes, providing unexplored opportunities for drug development in oncology. By integrating the druggable genome and the cancer genome, our study thus generates a comprehensive blueprint of potential druggable genes across cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505 · cited 2×
“…estimated to be part of PDGs whose activities may be modulated by pharmaceuticals (Brown et al., 2018; Campbell et al., 2012; Finan et al., 2017; Hopkins and Groom, 2002; Kumar et al., 2013; Overington et al., 2006; Rask-Andersen et al., 2011, 2014; Russ and Lampel, 2005; Southan et al., 2015).”
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 8×
“To define the potentially druggable genes (PDGs), candidates from 6 comprehensive druggable gene resources (Carvalho-Silva et al., 2019; Finan et al., 2017; Hopkins and Groom, 2002; Kumar et al., 2013; Russ and Lampel, 2005; Southan et al., 2015) were integrated.”
InfluentialOncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201 · cited 1×
“…provided a power tool for identification and prioritization of drug targets in oncology (Bailey et al., 2018; Beroukhim et al., 2010; Garraway and Lander, 2013; Kandoth et al., 2013; Lawrence et al., 2013; Sanchez-Vega et al., 2018; Vogelstein et al., 2013; Yuan et al., 2014; Zack et al., 2013).”
Self-citationA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256 · cited 1×
“Characterization of recurrent genomic alterations has provided a power tool for identification and prioritization of drug targets in oncology (Bailey et al., 2018; Beroukhim et al., 2010; Garraway and Lander, 2013; Kandoth et al., 2013; Lawrence et al., 2013; Sanchez-Vega et al., 2018; Vogelstein…”
Self-citationMeyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952
Toil enables reproducible, open source, big biomedical data analyses
Vivian, J., Rao, A. A., Nothaft, F. A., Ketchum, C., Armstrong, J., Novak, A., Pfeil, J., Narkizian, J., Deran, A. D., Musselman-Brown, A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3772 · Cited by 1,365 · cited 1×
“All RNA-seq data were processed through a pipeline developed by the UCSC Toil RNAseq Recompute Compendium, which allowed us to consistently process large-scale RNA-seq data without computational batch effects (Vivian et al., 2017).”
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Yanai, I., Benjamin, H., Shmoish, M., Chalifa-Caspi, V., Shklar, M., Ophir, R., Bar-Even, A., Horn-Saban, S., Safran, M., Domany, E., et al. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti042 · Cited by 1,300 · cited 1×
“The features in expression module included: 1) Tau tissue-specificity index (Yanai et al., 2005) assessing cancer type/tissue specificity across TCGA cancer types.”
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 2×
“Recent advances in KRAS (G12C) inhibitors have shifted this paradigm, and several KRAS inhibitors are advanced in early clinical trials (Moore et al., 2020).”
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · cited 3×
“However, although it has been proposed for over two decades that a gene with hemizygous loss may cause vulnerabilities in cancer (Frei, 1993; Kronke et al., 2015; Nichols et al., 2020; Nijhawan et al., 2012; Paolella et al., 2017; Rendo et al., 2020), no SCNA loss /group II gene has directly…”
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · cited 2×
“…estimated to be part of PDGs whose activities may be modulated by pharmaceuticals (Brown et al., 2018; Campbell et al., 2012; Finan et al., 2017; Hopkins and Groom, 2002; Kumar et al., 2013; Overington et al., 2006; Rask-Andersen et al., 2011, 2014; Russ and Lampel, 2005; Southan et al., 2015).”
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
Pharmacogenomic agreement between two cancer cell line data sets
The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium (2015) · Nature · doi:10.1038/nature15736 · Cited by 418
PubTator central: automated concept annotation for biomedical full text articles
Wei, C.-H., Allot, A., Leaman, R., & Lu, Z. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz389 · Cited by 400
Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296 · cited 17×
“Strategies to identify and prioritize druggable targets for cancer treatment would represent a significant advance in therapeutic development in oncology (Rubio-Perez et al., 2015; Yap and Workman, 2012).”
InfluentialRask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282 · cited 2×
“…estimated to be part of PDGs whose activities may be modulated by pharmaceuticals (Brown et al., 2018; Campbell et al., 2012; Finan et al., 2017; Hopkins and Groom, 2002; Kumar et al., 2013; Overington et al., 2006; Rask-Andersen et al., 2011, 2014; Russ and Lampel, 2005; Southan et al., 2015).”
Pharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279 · cited 4×
“2.0; http://juniper.health.unm.edu/tcrd/) from the IDG project of NIH (Nguyen et al., 2017).”
Influential
Cited by
PubTator 3.0: an AI-powered literature resource for unlocking biomedical knowledge
Wei, C.-H., Allot, A., Lai, P.-T., Leaman, R., Tian, S., Luo, L., Jin, Q., Wang, Z., Chen, Q., & Lu, Z. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae235 · Cited by 176
Umbaugh, C. S., Groth, M., Erkut, C., Lee, K.-S., Marinho, J., Linder, S., Iser, F., Kapp, J. N., Schroeter, P., Dolaner, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2796 · Cited by 6
(2023) · doi:10.1101/2023.02.28.530483 · Cited by 5
Richardson, R. A., Navarro, H. T., Nunes Amaral, L. A., & Stoeger, T. (2024) · doi:10.7554/elife.93429.2
Metadata
- Authors
- Jiang, J., Yuan, J., Hu, Z., Zhang, Y., Zhang, T., Xu, M., Long, M., Fan, Y., Tanyi, J. L., Montone, K. T., Tavana, O., Vonderheide, R. H., Chan, H. M., Hu, X., & Zhang, L.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 38
- Issue
- 8
- Pages
- 110400
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W4214719698
- Cited by
- 45
- References
- 21
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.